TY - JOUR
T1 - Consumer willingness to pay for a hypothetical Chagas disease vaccine in Brazil
T2 - A cross-sectional study and the implications
AU - Athie, Thannuse Silva
AU - Nascimento, Gesiane Cavalcante
AU - Da Costa, Maria José Labis
AU - De Sales Silva, Juliana
AU - Reis, Edna Afonso
AU - Martin, Antony Paul
AU - Godman, Brian
AU - Godoí, Isabella Piassi Dias
N1 - Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.
PY - 2021/6
Y1 - 2021/6
N2 - Aim: Chagas disease is a serious public health problem, endemic in 21 countries in Latin America. A future vaccine can contribute to decreasing the number of cases and its complications. Methods: A cross-sectional study was conducted with residents of the northern region of Brazil, on the willingness to pay for a hypothetical vaccine against Chagas disease (effective protection of 80%). Results: We interviewed 619 individuals and seven were excluded from the analysis and the value of willingness to pay was US$23.77 (100.00 BRL). Conclusion: The Northern region of Brazil is one of the largest markets for this vaccine, due to its epidemiological relevance, so economic studies with this vaccine will be important to assist in the assessment of technologies.
AB - Aim: Chagas disease is a serious public health problem, endemic in 21 countries in Latin America. A future vaccine can contribute to decreasing the number of cases and its complications. Methods: A cross-sectional study was conducted with residents of the northern region of Brazil, on the willingness to pay for a hypothetical vaccine against Chagas disease (effective protection of 80%). Results: We interviewed 619 individuals and seven were excluded from the analysis and the value of willingness to pay was US$23.77 (100.00 BRL). Conclusion: The Northern region of Brazil is one of the largest markets for this vaccine, due to its epidemiological relevance, so economic studies with this vaccine will be important to assist in the assessment of technologies.
KW - Brazil
KW - Chagas disease
KW - contingent valuation
KW - vaccine
KW - willingness to pay
UR - http://www.scopus.com/inward/record.url?scp=85105913131&partnerID=8YFLogxK
U2 - 10.2217/cer-2020-0241
DO - 10.2217/cer-2020-0241
M3 - Article
C2 - 33851872
AN - SCOPUS:85105913131
SN - 2042-6305
VL - 10
SP - 659
EP - 672
JO - Journal of Comparative Effectiveness Research
JF - Journal of Comparative Effectiveness Research
IS - 8
ER -